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Abstract
A new, simple and repeatable liquid chromatography method with charged aerosol detec-
tion (LC-CAD) for the determination of gentamicin sulphate composition and related sub-
stances has been developed. Gentamicin lacks of chromophores, therefore its determination
is quite problematic. Using a universal CAD enables to achieve good separation without
sample derivatization. Mass spectrometry was employed to conﬁrm the LC-CAD peak proﬁle.
The proposed method was validated and applied for the determination of gentamicin sul-
phate composition and related substances in pharmaceutical preparations.
Keywords
Column liquid chromatography
Charged aerosol detection
Gentamicin sulphate
Sisomicin sulphate
Introduction
Gentamicin sulphate is an aminoglyco-
side antibiotic formulated by fermenta-
tion of Micromonospora purpurea [1],
used in therapy against Gram-negative
bacteria [2]. It is a mixture of com-
pounds, the major components are gen-
tamicins C1, C1a, C2, C2a and a minor
one C2b. Also, the related substances
like sisomicin, garamine, gentamicin B1,
2-deoxystreptamine are formed in small
amounts during fermentation [3, 4].
Although all are structurally similar, the
antimicrobial potency as the toxicity are
diﬀerent, so there is strong need to con-
trol the amount of main components as
well as the related substances in com-
mercial samples.
Gentamicin’s high polarity, non-vol-
atility and lack of chromophore make
the chromatographic analysis quite
problematic. European Pharmacopoeia
6.8. (Ph. Eur. 6.8.) recommends LC with
pulsed electrochemical detection (LC-
PED) [5], however, this method possesses
problems with reproducibility, separa-
tion and robustness. Few improvements
of LC-PED have been published [6–9],
but still it is not reproducible enough.
Thus other methods, direct and indirect,
have been proposed. The indirect meth-
ods required pre- or post-column deriva-
tization with either UV [10–13]o r
ﬂuorescence detection [14–17]o rC E[ 18,
19], were time consuming, tedious and
not accurate enough. Direct methods in-
cluded detection techniques such as
refractive index (RI) [20], ELSD [21, 22],
CAD [23], CE [24], ED [25, 26]o rM S
[27–29]. The advantages and disadvan-
tages of these methods were discussed in
[7, 23, 30]. And only few methods for the
related substances determination have
been reported [7, 18, 21, 23, 31].
The aim of this work was to develop a
quick,simple,relativelysensitiveandrepeat-
able LC-CAD method without derivatiza-
tion for the determination of ﬁve speciﬁed
gentamicin sulphate components: C1, C1a,
C2, C2a and C2b and related substances,
which could be applied for routine anal-
ysis of these compounds in substance and
in pharmaceutical preparations.
Although recently a similar applica-
tion has been reported [23] there are a few
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reproducible. Instead of a short penta-
ﬂuorophenyl column used in the men-
tioned application, in this work a more
common C18 column was used success-
fully. The analysis time is almost two
timesshorterandonlyonemobilephaseis
used. In contrast to the previous applica-
tion this method was successfully applied
to the pharmaceuticals from diﬀerent
manufacturers, not only to one speciﬁc
product. Also, the optimized chromato-
graphicconditionsinLC-CADhavebeen
applied straightforward to LC–ESI–MS
analysis for peaks identiﬁcation.
The proposed LC-CAD method also
has a few advantages over the LC-PED
compendial method [5]. The most
important is that the peaks due to all
gentamicin components are completely
resolved, as well as the peaks due to the
related substances, eluting before genta-
micin C1a. In addition, the peak sym-
metry is almost ideal and analysis time is
over three times shorter.
All above mentioned reasons show
the proposed method with Corona CAD
is suitable for the purpose of this work.
The Corona CAD is a new type of
detector [32, 33] introduced for LC
applications and has recently become
widely employed in pharmaceutical
analyses [34–40].
Experimental
Chemicals and Materials
All reagents were LC grade. Acetonitrile
and methanol were from Labscan, triﬂu-
oroacetic acid (TFA) from AppliChem,
formic acid (FA) from Park Scientiﬁc.
Doubly distilled water additionally puri-
ﬁed in the nanopure diamond UV deion-
ization system from Barnstead was used
throughout. Reference standards: Gen-
tamicin sulphate and sisomicin sulphate
from EDQM. Pharmaceutical prepara-
tions: Gentamicin USP, a solution for
injections from KRKA (Novo Mesto,
Slovenia) and Gentamicin, a solution
for injections from Polfa Tarchomin
(Warsaw, Poland), both containing
40 mg mL
-1 of gentamicin.
Equipment and Conditions
An LC Ultimate 3000 Dionex system
consisting of: a pump, a degasser, an
autosampler, a column heater and a
pulse damper coupled with an ESA
Corona CAD instrument was used.
CAD response range was 100 pA, no
ﬁlter selected. Nitrogen gas from nitro-
gen generator, regulated at 35 psi, was
introduced to the detector. Data pro-
cessing was carried out with Chromeleon
6.8 and Chromeleon Validation ICH
software (Dionex) and chromatographic
conditions optimization with DryLab
2000 Plus software (Molnar Institute).
For peak elution order determination
a mass spectrometer MicrOTOF-Q II
from Bruker Daltonic was used. Chro-
matographic conditions for MS analysis
were the same as in LC-CAD. The MS
settings were: electrospray ionization
(ESI) in the positive ion mode, dry gas
(nitrogen) ﬂow rate 8.0 L min
-1, the dry
heater 180 C, the capillary voltage
4,500 V and end plate oﬀset -500 V.
MS data were recorded in full scan mode
(from 50 to 800 m/z).
Standard Solutions
Preparation
The standards of analyzed substances
were accurately weighed into volumetric
ﬂasks and dissolved with the 55 mM
TFA (solvent) to produce stock solu-
tions, which were successively diluted
with the solvent to obtain required con-
centrations.
Sample Solutions Preparation
The concentrations of gentamicin in
sample solutions were: ca. 200 lgm L
-1
for determination of gentamicin sulphate
composition and ca. 500 lgm L
-1 for
determination of impurities. All dilu-
tions were made in 55 mM TFA.
Results and Discussion
Method Development
The hydrophilic nature of gentamicin
demands the use of highly aqueous
mobile phase with addition of an ion-
pair agent. The diﬀerent water–methanol
mobile phases with addition of TFA or
FA in water in isocratic and gradient
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Fig. 1. LC-CAD chromatogram of the artiﬁcial mixture containing 200 lgm L
-1 gentamicin
and 3 lgm L
-1 of sisomicin (a) and the solution containing 250 lgm L
-1 gentamicin in
pharmaceutical preparation (b). m/z of protonated molecule from MS scan evaluated in the same
chromatographic conditions
1226 Chromatographia 2010, 72, December (No. 11/12)Limited Short Communicationelution modes were investigated. Iso-
cratic condition and TFA addition were
suitable for satisfactory peak separation.
The content of methanol and TFA in the
mobile phase was optimized using Dry-
Lab. The best resolution was obtained
with a Hypersil Gold C18 analytical
column (150 9 4.6 mm; 3 lm) from
Thermo Scientiﬁc in isocratic mode with
the mobile phase consisting of 55 mM
TFA:methanol:acetonitrile (98:1:1, v/v/v).
To avoid column dewetting as a result of
using highly aqueous mobile phase, the
column was ﬂushed with acetonitrile:
water (80:20, v/v) for 20 min at the end
of each day. The eﬀect of diﬀerent ﬂow
rates (from 0.4 to 0.6 mL min
-1) and
column temperature (from 20 to 30 C)
on the peak resolution was studied. A
ﬂow rate was set at 0.5 mL min
-1,2 5C
were used throughout and injection
volume was 10 lL. These conditions
were optimal for the separation of
ﬁve main gentamicin components and
related substances with good resolution
in 20 min (Fig. 1).
Peaks Assignment
As the standards of gentamicin compo-
nents were not available, the peak elu-
tion order was determined according to
LC–ESI–MS spectra and the relative
proportions described in Ph. Eur. [5].
Sisomicin was identiﬁed by the retention
time of the standard. Additionally other
compounds eluting before gentamicin
C1a were found, two of them were
identiﬁed as garamine and gentamicin A
based on [M + H]
+ m/z value.
Method Validation
The method was validated according to
ICH guidelines [41]. The data concerning
method validation are summarized in
Table 1. Peak areas were evaluated in
the whole validation. Due to the lack of
reference standard material of individual
gentamicin components, series of work-
ing solutions of gentamicin sulphate
standard with known total gentamicin
concentration (calculated by subtraction
of sulphate, impurities and water con-
tent) were used in the entire validation,
however, the peak areas of each indi-
vidual component were concerned.
The linearity was estimated by ana-
lyzing gentamicin sulphate and sisomicin
sulphate standards. Seven concentra-
tions ranging from 10 to 500 lgm L
-1
for gentamicin and ﬁve concentra-
tions ranging from 2.5 to 50 lgm L
-1
for sisomicin were used to obtain the
calibration curves. In the ranges investi-
gated there were no signiﬁcant diﬀer-
ences in the coeﬃcient of determination
values (R
2) between linear and power
function. Although it is known that
CAD response is nonlinear at a range of
four orders of magnitude, the signal
is nearly linear in the smaller ranges
[42, 43].
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Limited Short Communication Chromatographia 2010, 72, December (No. 11/12) 1227The detection limit (LOD) and
quantitation limit (LOQ) were deﬁned as
signal-to-noise ratio of 3:1 and 10:1.
The accuracy of the recovery and the
repeatability were assessed using linear
response function at three concentrations
covering the speciﬁed range. The mean
recoveries were in the range of 98.3–
101.6%. The precisions were calculated
from threeconsecutive injections foreach
concentration and the observed RSD
ranged from 0.04 to 0.73%. Intermediate
precision was calculated from 2 days.
Method robustness was evaluated
during method development. Method
was robust for column temperature
±3 C, ﬂow rate ±20%, TFA content
±5 mM. For all parameter variations
the minimum Rs value between critical
pair of peaks was >1.5.
Application to Pharmaceutical
Preparations
Three pharmaceuticals from two manu-
facturers were investigated. From
KRKA two batches: signed A and B,
3 years expired and not expired, respec-
tively, and from Polfa batch C, 4 years
expired. The excipients composition in
pharmaceuticals from each manufac-
turer was diﬀerent. Expired samples
were analyzed as they were supposed to
have higher impurities content.
Gentamicin sulphate composition
was calculated using a normalization
procedure [5, 10] and related substances
by comparing with sisomicin sulphate
standard [8].
Slight diﬀerences in the component
content and in the impurities proﬁle were
observed; however, for every sample
gentamicincompositionwasinagreement
with the pharmacopoeial requirements
(Table 1), as the sisomicin and other
impuritiescontent,whichwaslessthan0.6
and 2.5%, respectively, even for expired
samples. RSD values were better than
2%, except for gentamicin C2b described
as a minor component (1–2%, m/m).
Conclusion
The elaborate method proved to be fast,
precise, accurate and sensitive and has
been successfully used in analyzing
commercial samples from diﬀerent
manufacturers. By comparison with
previously developed LC methods, the
improvements of this method are: short
analysis time with good resolution,
sensitivity and great reproducibility.
Also, the optimized chromatographic
conditions in LC-CAD can be applied
straightforward to LC–ESI–MS analysis
for peak identiﬁcation which can be
extremely useful as the impurities proﬁle
can diﬀer from one another between
gentamicin sulphate manufacturers.
Thus this method seems to be useful for
quality analysis of the substance and
pharmaceutical preparations for diﬀer-
ent QC laboratories.
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